Neuroprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on spinal cord injury

J Mol Neurosci. 2012 Nov;48(3):508-17. doi: 10.1007/s12031-012-9817-2. Epub 2012 Jun 7.

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuroprotective peptide expressed in the central nervous system. To date, changes in the expression and effect of endogenous PACAP have not been clarified with respect to spinal cord injury (SCI). The aim of this study was to elucidate the expression pattern and function of endogenous PACAP on the contusion model of SCI using heterozygous PACAP knockout (PACAP(+/-)) and wild-type mice. Real-time polymerase chain reaction methods revealed that the level of PACAP mRNA increased gradually for 14 days after SCI and that PAC1R mRNA levels also increased for 7 days compared with intact control mice. PACAP and PAC1R immunoreactivities colabeled with a neuronal marker in the intact spinal cord. Seven days after SCI, PAC1R immunoreactivity was additionally co-expressed with an astrocyte marker. Wild-type mice gradually recovered motor function after 14 days, but PACAP(+/-) mice showed significantly impaired recovery from 3 days compared with wild-type mice. The injury volume at day 7 in PACAP(+/-) mice, and the number of single-stranded DNA-immunopositive cells as a marker of neuronal cell death at day 3 were significantly higher than values measured in wild-type mice. These data suggest that endogenous PACAP is upregulated by SCI and has a neuroprotective effect on the damaged spinal cord.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / metabolism
  • Cell Death
  • Drug Evaluation, Preclinical
  • Gene Expression Regulation
  • Genotype
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nerve Tissue Proteins / biosynthesis
  • Nerve Tissue Proteins / deficiency
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / physiology*
  • Neurons / pathology
  • Pituitary Adenylate Cyclase-Activating Polypeptide / biosynthesis
  • Pituitary Adenylate Cyclase-Activating Polypeptide / deficiency
  • Pituitary Adenylate Cyclase-Activating Polypeptide / genetics
  • Pituitary Adenylate Cyclase-Activating Polypeptide / physiology*
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • Real-Time Polymerase Chain Reaction
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / biosynthesis
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / genetics
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / physiology
  • Recovery of Function
  • Spinal Cord Injuries / genetics
  • Spinal Cord Injuries / pathology
  • Spinal Cord Injuries / physiopathology*
  • Time Factors
  • Up-Regulation

Substances

  • Adcyap1 protein, mouse
  • Adcyap1r1 protein, mouse
  • Nerve Tissue Proteins
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • RNA, Messenger
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I